ESR1 and breast carcinoma: Our analysis revealed that a high expression of IGF-1 or IGF-1R (or both) does not affect the OS or DFS rates in patients with ER/PR-positive and HER2-negative breast cancer subtype, but it associates with a reduced DFS rate in TNBC patients.